ResearchSafe

Recent PE 22-28 preprint sparks curiosity – what do you think?

Posted by nof1_weekend in Research & News - 14 points, 4 comments.

613278). The authors report that a single dose increased markers of synaptogenesis in the prefrontal cortex within 24 hours, which they link to faster antidepressant-like behavior compared to standard SSRIs. Tbh the speed of the effect caught my eye because I’ve been experimenting with low‑dose nootropic stacks for mood stability and the idea of a peptide that works on TREK‑1 channels feels novel.

The data are still preclinical, so I’m cautious about jumping to human use, but the mechanism lines up with what we know about serotonergic signaling and neuroplasticity. I wonder if anyone here has seen follow‑up work or is tracking any early human safety trials? Would love to hear thoughts on whether this looks like a promising lead or just another interesting lab tool that won’t translate.

Comments

  • benchpr_chemist64: Honestly the speed of that effect is wild, makes me wonder if I’m just chasing the next shiny thing in my low‑dose nootropic stack for mood swings. To be fair I’ve noticed a subtle bump in focus when I throw in a bit of racetam with L‑theanine, but nothing that feels like a game‑changer. I haven’t seen any human safety data on PE 22‑28 yet, so I’m sticking to the “wait for the trial” camp until we get more than rodent synaptogenesis numbers. Anyone else tracking early phase stuff?
  • nof1_weekend: Yeah the racetam‑L‑theanine combo giving you a subtle focus bump matches what I’ve felt with my low‑dose stack, nothing earth‑shaking but a nice edge. I’ve been scanning ClinicalTrials.gov weekly for any PE 22‑28 entries; so far nothing posted. Have you checked the EU Clinical Trials Register too?
  • fasted_scientist: Ngl the 24‑hour synaptogenesis jump is eye‑catching, but without human safety or pharmacokinetic data it’s still a guess. Have you seen any phase‑I trial registrations for PE 22‑28, or are we all just waiting for the first human read‑out?
  • nof1_weekend: I haven’t spotted any phase‑I entries for PE‑22‑28 on clinicaltrials.gov or EU registers yet, so I’m also just watching for the first human safety read‑out. If anything pops up I’ll post the link here.

Community discussion - research and educational context only. Not medical advice.